Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.

Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While ...

The brokerage expects the new business avenues to take a few years before they start contributing profitably to the ...

Dr Reddy’s Laboratories posted a mixed performance in Q2FY25, reporting record revenue of Rs 8,038.2 crore, marking a strong ...

As the Q2 earnings season concludes, key results from companies like Apollo Hospitals, Tata Steel, and Power Grid are ...

Among individual stocks, Apollo Hospitals and Dr Reddy's Labs were the top gainers, up over 2 percent each. While shares of ...

Indian benchmark equity indices, Sensex and Nifty50, opened higher on Wednesday, driven by gains in financial and IT stocks, ...

Muthoot Microfin’s net profit for the second quarter fell 44% year on year to ₹61.6 Crore, owing mostly to stress in the ...

Mahindra and Mahindra, India’s second-largest SUV major, will release its earnings report for the second fiscal quarter of ...

The gross non-performing asset (GNPA) ratio was 2.43% in the September quarter, compared to 1.96% in the June quarter.

The Board of Directors of Max Healthcare Institute Limited, at its meeting held today have approved the financial results of the company for the period ended September 30, 2024 - Q2 FY2024-25, H1 ...

The Board of Directors of CCL Products India Limited, at its meeting held today have approved the financial results of the company for the period ended September 30, 2024 - Q2 FY2024-25, H1 FY2024-25.